Immuron Business Update: Letter to Shareholders
22 juin 2023 06h00 HE
|
Immuron Limited
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Initiates Recruitment of Travelan® Clinical Study
30 mai 2023 06h00 HE
|
Immuron Limited
Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
18 janv. 2023 05h00 HE
|
Immuron Limited
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in...
Immuron Submits IND Application To FDA for Travelan
05 déc. 2022 06h00 HE
|
Immuron Limited
Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the...
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
04 oct. 2022 06h00 HE
|
Immuron Limited
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in...
IMM-124E – Demonstrates Antiviral T-Cell Immunity
08 oct. 2021 06h00 HE
|
Immuron Limited
Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical...
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
13 mai 2021 06h00 HE
|
Immuron Limited
Key Points Monash University Research Update on SARS-CoV-2 programBiomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief...
Immuron Travelers’ Diarrhea Market Update
12 oct. 2020 06h00 HE
|
Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
12 juin 2019 07h00 HE
|
Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
Immuron sales surge by 66% in the Third Quarter of FY19
15 avr. 2019 09h00 HE
|
Immuron Limited
Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...